Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer1

Glenn Liu, Yu Hui Chen, Jill Kolesar, Wei Huang, Robert DiPaola, Michael Pins, Michael A Carducci, Mark Stein, Glenn J. Bubley, George Wilding

Research output: Contribution to journalArticle

Abstract

Purpose: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. Patients and methods: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT)

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Androgens
Prostate
Prostatic Neoplasms
Androgen Receptors
Epidermal Growth Factor
Genes
lapatinib
Therapeutics

Keywords

  • Clinical trial
  • Epidermal growth factor receptor
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer1. / Liu, Glenn; Chen, Yu Hui; Kolesar, Jill; Huang, Wei; DiPaola, Robert; Pins, Michael; Carducci, Michael A; Stein, Mark; Bubley, Glenn J.; Wilding, George.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 31, No. 2, 02.2013, p. 211-218.

Research output: Contribution to journalArticle

Liu, Glenn ; Chen, Yu Hui ; Kolesar, Jill ; Huang, Wei ; DiPaola, Robert ; Pins, Michael ; Carducci, Michael A ; Stein, Mark ; Bubley, Glenn J. ; Wilding, George. / Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer1. In: Urologic Oncology: Seminars and Original Investigations. 2013 ; Vol. 31, No. 2. pp. 211-218.
@article{f82cbe294e874495b61d7ee947318c76,
title = "Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer1",
abstract = "Purpose: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. Patients and methods: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT)",
keywords = "Clinical trial, Epidermal growth factor receptor, Tyrosine kinase inhibitors",
author = "Glenn Liu and Chen, {Yu Hui} and Jill Kolesar and Wei Huang and Robert DiPaola and Michael Pins and Carducci, {Michael A} and Mark Stein and Bubley, {Glenn J.} and George Wilding",
year = "2013",
month = "2",
doi = "10.1016/j.urolonc.2011.01.002",
language = "English (US)",
volume = "31",
pages = "211--218",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer1

AU - Liu, Glenn

AU - Chen, Yu Hui

AU - Kolesar, Jill

AU - Huang, Wei

AU - DiPaola, Robert

AU - Pins, Michael

AU - Carducci, Michael A

AU - Stein, Mark

AU - Bubley, Glenn J.

AU - Wilding, George

PY - 2013/2

Y1 - 2013/2

N2 - Purpose: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. Patients and methods: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT)

AB - Purpose: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. Patients and methods: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT)

KW - Clinical trial

KW - Epidermal growth factor receptor

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84875275330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875275330&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2011.01.002

DO - 10.1016/j.urolonc.2011.01.002

M3 - Article

C2 - 21784672

AN - SCOPUS:84875275330

VL - 31

SP - 211

EP - 218

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -